Compare ResMed Inc. (RMD) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Spotify Technology — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Spotify Technology trades at $523.96 (market cap $108.68B). The key difference: Spotify Technology is far larger — about 3.4× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.19% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.
| RMD | SPOT | |
|---|---|---|
Market Cap | $31.89B | $108.68B |
Sector | Health | Media |
52-Week High | $283.28 | $738.53 |
52-Week Low | $182.82 | $412.75 |
Enterprise Value | $31.24B | $98.31B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Spotify (SPOT) trades at $528.64, down 2.54% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend in moving averages but neutral oscillators, with key support at $524 and resistance at $535. Fundamentally, the company reported strong revenue growth to $17.19B in 2025 and a net income margin of 12.87%, though it missed Q2 2026 EPS estimates. Recent news highlights a $1.5B share repurchase program expansion and initiatives to label AI-generated content.
The outlook for SPOT is supported by robust earnings growth, cash flow generation, and analyst optimism, with a consensus price target of $590.29. However, risks include premium valuation multiples, competitive pressures in audio streaming, and execution challenges in sustaining high growth rates. Investor sentiment remains positive given institutional buy ratings, but volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
